Literature DB >> 6214262

[Antibacterial activity of N-formimidoyl-thienamycin in comparison with other beta-lactam antibiotics against clinical problem strains (author's transl)].

H Grimm.   

Abstract

The efficacy of N-formimidoyl-thienamycin (MK 0787) has been tested against 549 cultures of different species, which often cause therapeutic problems. Included were 286 mezlocillin-resistant strains, 100 Serratia marcescens and 66 Pseudomonas aeruginosa. The minimal inhibitory concentration ranged between 0.06 and 4 micrograms/ml by means of the agar-dilution-method. Resistant strains were not observed. Among the 11 beta-lactam- and aminoglycoside-antibiotics tested N-formimidoyl-thienamycin was the most effective with the broadest spectrum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214262

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  [Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery].

Authors:  M Mayer; J Brand; D Schlenkhoff; W Opferkuch
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].

Authors:  K G Naber; D Adam; A Bauernfeind; E Hönig
Journal:  Infection       Date:  1986       Impact factor: 3.553

3.  Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.

Authors:  M Mayer; C Tophof; W Opferkuch
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

4.  Discrepancies in susceptibility test results for imipenem employing different in vitro test methods and DIN 58,940 breakpoints.

Authors:  H Grimm; C Hauss; A C Rodloff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

5.  [Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery].

Authors:  M Wenzel; H Loch
Journal:  Infection       Date:  1986       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.